On Monday, Divi Laboratories consolidated net profit, which has been increased by 78 per cent to Rs 895 crore in the fourth quarter on March 31, 2022. In the last quarter, the drugmaker has reported a net profit of Rs 502 crore, and revenue from operation rose to Rs 2 518 crores, against Rs 1 788 crore in the year-ago period, as per the company’s statement.

• Inkers Technology Secures $3 Million in Funding 
• Zomato Shares Slump 2% on Receiving Rs 803 Crore GST Tax Notice 
• Bajel Projects Shares Skyrocketed 15% on Order from Solapur Transmission
• AVG Logistics Shares Trade 2% Higher on Bagging Rs 90 Crore Order 
• Hindustan Aeronautics Shares Gain 2% on Contract with MoD

For the year ended in March 2022, Divi Laboratories Ltd posted a consolidated net profit of Rs 2,960 crore against Rs 1,984 crore in FY21.

Revenue from operations rose to Rs 8,960 crore compared to Rs 6,969 crore in 2020-21.
The company said its board had recommended a dividend of Rs 30 per share of the face value of Rs 2 (1,500 per cent) for 2021-22, subject to members’ approval at the ensuing annual general meeting.

Shares of the company were trading 6.37 per cent down at Rs 4,032.35 apiece on the Bombay Stock Exchange (BSE).